An expert opinion piece highlighted the potential of combining regulatory T-cell-targeted therapies using dominant HSP peptides with current biological therapies for autoimmune and inflammatory conditions such as atherosclerosis [78]. This evidence concerns the gene HSP90B2P and atherosclerosis.